دورية أكاديمية
أعرض في EDS

Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage.

التفاصيل البيبلوغرافية
العنوان: Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage.
المؤلفون: Alessi I; Department of Hematology/Oncology, Gene Therapy and Hematopoietic Transplantation, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Caroleo AM; Department of Hematology/Oncology, Gene Therapy and Hematopoietic Transplantation, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., de Palma L; Child Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Mastronuzzi A; Department of Hematology/Oncology, Gene Therapy and Hematopoietic Transplantation, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Pro S; Child Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Colafati GS; Neuroradiology Unit, Imaging Department, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Boni A; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, 00161 Rome, Italy., Della Vecchia N; Department of Emergency, Acceptance and General Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Velardi M; Child Neurology, NESMOS Department, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy., Evangelisti M; Child Neurology, NESMOS Department, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy., Carboni A; Neuroradiology Unit, Imaging Department, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Carai A; Neurosurgery Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Vinti L; Department of Hematology/Oncology, Gene Therapy and Hematopoietic Transplantation, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Valeriani M; Child Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Reale A; Department of Emergency, Acceptance and General Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Parisi P; Child Neurology, NESMOS Department, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy., Raucci U; Department of Emergency, Acceptance and General Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
المصدر: Cancers [Cancers (Basel)] 2022 Mar 17; Vol. 14 (6). Date of Electronic Publication: 2022 Mar 17.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Neurotoxicity caused by traditional chemotherapy and radiotherapy is well known and widely described. New therapies, such as biologic therapy and immunotherapy, are associated with better outcomes in pediatric patients but are also associated with central and peripheral nervous system side effects. Nevertheless, central nervous system (CNS) toxicity is a significant source of morbidity in the treatment of cancer patients. Some CNS complications appear during treatment while others present months or even years later. Radiation, traditional cytotoxic chemotherapy, and novel biologic and targeted therapies have all been recognized to cause CNS side effects; additionally, the risks of neurotoxicity can increase with combination therapy. Symptoms and complications can be varied such as edema, seizures, fatigue, psychiatric disorders, and venous thromboembolism, all of which can seriously influence the quality of life. Neurologic complications were seen in 33% of children with non-CNS solid malign tumors. The effects on the CNS are disabling and often permanent with limited treatments, thus it is important that clinicians recognize the effects of cancer therapy on the CNS. Knowledge of these conditions can help the practitioner be more vigilant for signs and symptoms of potential neurological complications during the management of pediatric cancers. As early detection and more effective anticancer therapies extend the survival of cancer patients, treatment-related CNS toxicity becomes increasingly vital. This review highlights major neurotoxicities due to pediatric cancer treatments and new therapeutic strategies; CNS primary tumors, the most frequent solid tumors in childhood, are excluded because of their intrinsic neurological morbidity.
References: Clin EEG Neurosci. 2014 Jul;45(3):222-5. (PMID: 24151171)
Ann Oncol. 2016 Sep;27(suppl 5):v83-v90. (PMID: 27664263)
Cancer Discov. 2018 Jun;8(6):750-763. (PMID: 29563103)
Pharm World Sci. 2010 Apr;32(2):109-11. (PMID: 20033290)
Neurosurgery. 2001 Aug;49(2):409-14; discussion 414-5. (PMID: 11504117)
J Adolesc Young Adult Oncol. 2019 Oct;8(5):593-601. (PMID: 31063432)
Blood. 2019 May 16;133(20):2212-2221. (PMID: 30808634)
J Clin Oncol. 2015 Jun 20;33(18):2092-9. (PMID: 25918278)
Pharmacoeconomics. 2012 Jul 1;30(7):537-49. (PMID: 22612993)
Antioxid Redox Signal. 2014 Mar 20;20(9):1410-22. (PMID: 23802883)
Neurooncol Pract. 2020 Oct 17;8(1):75-80. (PMID: 33664972)
Nat Rev Clin Oncol. 2012 Jul 03;9(8):471-8. (PMID: 22751283)
Pediatr Neurol. 2018 Aug;85:33-42. (PMID: 30126755)
Front Pediatr. 2017 May 15;5:105. (PMID: 28555178)
Neurol Sci. 2016 Jan;37(1):157-161. (PMID: 26466588)
Sci Transl Med. 2014 Feb 19;6(224):224ra25. (PMID: 24553386)
Neurology. 2013 Feb 19;80(8):747-53. (PMID: 23390169)
J Pediatr Intensive Care. 2014 Sep;3(3):169-181. (PMID: 31214464)
Brain. 2019 May 1;142(5):1334-1348. (PMID: 30891590)
Blood. 2013 Mar 7;121(10):1906-10. (PMID: 23299314)
Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. (PMID: 27209293)
J Immunother Cancer. 2019 May 22;7(1):134. (PMID: 31118078)
Clin Case Rep. 2020 May 28;8(9):1678-1681. (PMID: 32983475)
Cancers (Basel). 2021 Feb 25;13(5):. (PMID: 33669053)
J Neurol. 2011 Jun;258(6):1098-104. (PMID: 21373901)
Lancet. 1994 Jul 23;344(8917):224-7. (PMID: 7913156)
N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870)
Lancet. 2015 Feb 7;385(9967):517-528. (PMID: 25319501)
Cancer J. 2014 Mar-Apr;20(2):119-22. (PMID: 24667956)
Neurooncol Pract. 2020 Sep 28;8(1):31-39. (PMID: 33664967)
Brain Dev. 2011 Apr;33(4):283-8. (PMID: 20609541)
N Engl J Med. 2010 Nov 4;363(19):1812-21. (PMID: 21047225)
Acta Oncol. 2019 Oct;58(10):1457-1462. (PMID: 31271084)
Drugs. 2017 Mar;77(4):435-445. (PMID: 28190142)
J Natl Cancer Inst. 2014 Jul 30;106(8):. (PMID: 25080574)
Cells. 2021 Dec 17;10(12):. (PMID: 34944078)
Semin Radiat Oncol. 2017 Oct;27(4):332-339. (PMID: 28865516)
Neurooncol Adv. 2020 May 05;2(1):vdaa057. (PMID: 32642709)
Semin Pediatr Neurol. 2017 Feb;24(1):60-69. (PMID: 28779867)
Clin Pharmacol Ther. 2019 Dec;106(6):1268-1279. (PMID: 31152605)
Bone Marrow Transplant. 2017 Jan;52(1):159-162. (PMID: 27643866)
AJNR Am J Neuroradiol. 2013 Dec;34(12):2298-303. (PMID: 23788601)
Br J Radiol. 2014 Sep;87(1041):20140211. (PMID: 24968876)
Cancer Discov. 2018 Sep;8(9):1069-1086. (PMID: 30115704)
Nat Rev Clin Oncol. 2019 Jan;16(1):45-63. (PMID: 30082906)
J Neurooncol. 2015 May;122(3):421-9. (PMID: 25670390)
Ther Adv Hematol. 2016 Jun;7(3):142-56. (PMID: 27247755)
Front Oncol. 2012 Jul 19;2:73. (PMID: 22833841)
Radiat Res. 2005 Nov;164(5):662-8. (PMID: 16238444)
World Neurosurg. 2014 Jul-Aug;82(1-2):240.e7-12. (PMID: 23314030)
Ital J Pediatr. 2010 Feb 06;36:14. (PMID: 20181110)
J Clin Neurosci. 2013 Apr;20(4):485-502. (PMID: 23416129)
Lancet. 1981 Nov 7;2(8254):1015-8. (PMID: 6118478)
Cancer Metastasis Rev. 2020 Mar;39(1):3-23. (PMID: 31933235)
Blood. 2013 Jun 27;121(26):5154-7. (PMID: 23678006)
Pediatr Blood Cancer. 2020 Feb;67(2):e27999. (PMID: 31674724)
Redox Biol. 2016 Oct;9:144-156. (PMID: 27544883)
Clin Endocrinol (Oxf). 2002 Dec;57(6):713-7. (PMID: 12460319)
Radiol Oncol. 2019 Oct 25;53(4):388-396. (PMID: 31652121)
Ann Hematol. 2019 Jan;98(1):159-167. (PMID: 30238148)
J Clin Oncol. 2016 Dec 20;34(36):4381-4389. (PMID: 27998223)
Lancet Oncol. 2015 Jan;16(1):57-66. (PMID: 25524800)
Int J Radiat Biol. 2010 Feb;86(2):132-44. (PMID: 20148699)
Blood. 2012 Oct 4;120(14):2807-16. (PMID: 22896001)
Clin Nucl Med. 2010 Aug;35(8):583-5. (PMID: 20631504)
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. (PMID: 30592986)
J Immunol. 2014 Feb 15;192(4):1480-90. (PMID: 24442430)
Childs Nerv Syst. 2005 Aug;21(8-9):808-16. (PMID: 16075214)
Neurology. 2016 Apr 19;86(16):1553-6. (PMID: 26984943)
J Child Neurol. 2014 Mar;29(3):336-41. (PMID: 23364656)
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. (PMID: 28925994)
Int J Hematol. 2018 Dec;108(6):630-636. (PMID: 30182170)
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25. (PMID: 26314773)
Cancer Discov. 2018 Aug;8(8):958-971. (PMID: 29880584)
Neuroradiology. 2017 Feb;59(2):105-126. (PMID: 28255902)
J Clin Oncol. 2016 Apr 1;34(10):1104-11. (PMID: 26884582)
Neurology. 2017 Feb 21;88(8):789-796. (PMID: 28122904)
N Engl J Med. 2018 Feb 1;378(5):449-459. (PMID: 29385376)
Neurology. 2013 Sep 10;81(11):1014-7. (PMID: 23935180)
Cancer. 2014 Aug 15;120(16):2464-71. (PMID: 24771533)
N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
Curr Oncol Rep. 2010 Jan;12(1):50-9. (PMID: 20425608)
N Engl J Med. 2013 Apr 18;368(16):1509-1518. (PMID: 23527958)
Nat Med. 2018 Jun;24(6):739-748. (PMID: 29808007)
J Clin Oncol. 2005 Apr 1;23(10):2256-63. (PMID: 15800316)
CA Cancer J Clin. 2020 Mar;70(2):86-104. (PMID: 31944278)
Curr Opin Pediatr. 2019 Feb;31(1):28-34. (PMID: 30531222)
فهرسة مساهمة: Keywords: chemotherapy; neurotoxicity; pediatrics cancer
تواريخ الأحداث: Date Created: 20220325 Latest Revision: 20220329
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8946171
DOI: 10.3390/cancers14061540
PMID: 35326692
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14061540